REGULATORY

Debates on FY2025 Off-Year Price Revision Officially Set Sail at Chuikyo

By Ken Yoshino July 18, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s all-powerful reimbursement policy panel has kicked off discussions toward the next “off-year” drug price revision scheduled for FY2025. At its meeting on July 17, healthcare providers sought debates on whether the government should go ahead with the plan in…

To read the full story

Chuikyo OKs Plan for Drug Price Survey in FY2024
July 18, 2024

REGULATORY

Japan Panel to Review Pfizer’s Cancer Med Tukysa on January 29
January 16, 2026
Study Group Calls for Independent Body to Centrally Manage Whole Genome Data
January 16, 2026
Expert Calls for Full Verification of CEA Guidelines and Analytical Frameworks
January 16, 2026
Japan Sets New Pricing Rules for Conditionally Approved Regenerative Medicines, Starting with Elevidys
January 15, 2026
MHLW Orders Label Revisions for Aspirin, CAR-T Therapies, and Other Drugs
January 14, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…